Shanghai-based biopharmaceutical company Harbour BioMed today announced successful completion of a Series B+ round financing of US$75 million. New investors SK Holdings, Greater Bay Area Fund, Efung Capital, Zheshang Venture Capital and Zhejiang University Future Capital and JT New Century, as well as existing investors Legend Capital, AdvanTech and GIC participated in this round. The […]
Chinese Biotech Firm Harbour BioMed Raises $75 Million In Series B+ Round comes from China Money Network: Primary Data for China's Primary Markets! All Rights Reserved.